Boehringer Targets High Unmet Need With Spesolimab Filing
Could Be First EU Approved Drug For Generalized Pustular Psoriasis Flares
Boehringer Ingelheim files spesolimab in the EU, where it is a forerunner in the race to fill the unmet need in generalized pustular psoriasis flares.
